BEIJINGThe top leaders of two major pharmaceutical companies say further efforts are needed to shake up a promising Chinese drug market that has been beset by regulatory issues and deep inefficiencies Drug makers struggle to bring products to the market fast enough given regulatory difficulties said Eli Lilly  Co Chief Executive John C Lechleiter speaking on Monday on the sidelines of the APEC CEO Summit an event tied to a meeting in Beijing of leaders from the AsiaPacific Economic Cooperation countries